3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
40
Colorectal Neoplasms
9
Adenocarcinoma
8
Esophageal Neoplasms
7
Carcinoma, Hepatocellular
7
Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Adenocarcinoma Of Esophagus
5
Neoplasm Metastasis
4
Rectal Neoplasms
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Biliary Tract Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Metastatic Gastric Adenocarcinoma
2
Melanoma
2
Cholangiocarcinoma
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Lymphoma, Mantle-Cell
1
Locally Advanced Unresectable Gastric Adenocarcinoma
1
Liver Diseases
1
Head and Neck Neoplasms
1
HER2-positive Gastric Cancer
1
Interventions
tusamitamab ravtansine
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Gastric
×
Ramucirumab
×
Gastrointestinal
×
Clear all
NCT05071053
2025-08-22
CARMEN-GC01
Sanofi
Phase 2
Terminated
35 enrolled
14 charts